Video

Michael Yeaman: Building Optimism in the Field of Neuromyelitis Optica

Author(s):

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

As a Medical Advisor to the Guthy Jackson Charitable Foundation, Michael R. Yeaman, PhD, has seen the work of the foundation make a big impact in moving the treatment of NMO forward in just a few short years. While it may be a few years before treatments are approved for the treatment of NMO, Yeaman said that is still a brighter picture than patients and their providers had just a few short years ago.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.